Aberrant expression of the PRAC gene in prostate cancer

Lenka,Govinda; Weng,Wen-Hui; Chuang,Cheng-Keng; Ng,Kwai-Fong; Pang,See-Tong

doi:10.3892/ijo.2013.2117

Aberrant expression of the PRAC gene in prostate cancer

Authors:
- Govinda Lenka
- Wen-Hui Weng
- Cheng-Keng Chuang
- Kwai-Fong Ng
- See-Tong Pang
View Affiliations

Affiliations: Department of Chemical Engineering and Biotechnology, Institute of Biochemical and Biomedical Engineering, National Taipei University of Technology, Taipei, Taiwan, R.O.C., Division of Urology, Department of Surgery, Chang Gung Memorial Hospital, LinKou, School of Medicine, Chang Gung University, Tao-Yuan, Taiwan, R.O.C., Department of Pathology, Chang Gung Memorial Hospital, LinKou, School of Medicine, Chang Gung University, Tao-Yuan, Taiwan, R.O.C.
Published online on: October 2, 2013 https://doi.org/10.3892/ijo.2013.2117
Pages: 1960-1966

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Identification of aberrant expression patterns of genes in prostate cancer (PCa) is a key step towards the development of effective therapies. Prostate-specific antigen (PSA) levels are commonly measured for the early detection of PCa, but which itself is still not an ideal biomarker. We analysed the expression patterns of prostate cancer susceptibility candidate (PRAC) in prostate cancer. The PRAC gene is known to be commonly expressed in prostate tissue, rectum and colon. To provide clear insights into the expression patterns of PRAC in PCa, we examined the gene expression by quantitative real-time PCR (qRT-PCR), western blot analysis and immunohistochemistry (IHC). The results showed that PRAC expression levels in androgen‑insensitive cells (DU145 and PC3) are lower than those in androgen-sensitive cell lines (LNCaP, LNCaP-R and CW22R). However, treatment of the LNCaP cell line with androgen and anti-androgen demonstrated that PRAC is expressed in an androgen-independent manner. Further, PRAC expression was restored upon treatment of DU145 and PC3 cells with the methyltransferase inhibitor, 5-aza-2'-deoxycytidine (5-aza-CdR), which indicates the effect of methylation in the control of PRAC expression. In addition, IHC analysis revealed a significantly decreased immunoreactivity of PRAC protein in PCa tissues compared to benign prostatic hyperplasia (BPH) (p<0.0001). Thus, our findings suggest that the pathogenesis of PCa may be due to the expression levels of PRAC protein, and this protein can serve as a potential biomarker for the management of PCa.

View Figures

View References

1.	Pang ST, Fang X, Valdman A, Norstedt G, Pousette A, Egevad L and Ekman P: Expression of ezrin in prostatic intraepithelial neoplasia. Urology. 63:609–612. 2004. View Article : Google Scholar : PubMed/NCBI
2.	Obinata D, Takayama K, Urano T, et al: Oct1 regulates cell growth of LNCaP cells and is a prognostic factor for prostate cancer. Int J Cancer. 130:1021–1028. 2012. View Article : Google Scholar
3.	Garnick MB and Fair WR: Combating prostate cancer. Sci Am. 279:74–83. 1998. View Article : Google Scholar : PubMed/NCBI
4.	Gelmann EP: Molecular biology of the androgen receptor. J Clin Oncol. 20:3001–3015. 2002. View Article : Google Scholar : PubMed/NCBI
5.	Pang ST, Dillner K, Wu X, Pousette A, Norstedt G and Flores-Morales A: Gene expression profiling of androgen deficiency predicts a pathway of prostate apoptosis that involves genes related to oxidative stress. Endocrinology. 143:4897–4906. 2002. View Article : Google Scholar : PubMed/NCBI
6.	Sharma S, Kelly TK and Jones PA: Epigenetics in cancer. Carcinogenesis. 31:27–36. 2010. View Article : Google Scholar
7.	Feinberg AP, Ohlsson R and Henikoff S: The epigenetic progenitor origin of human cancer. Nat Rev Genet. 7:21–33. 2006. View Article : Google Scholar : PubMed/NCBI
8.	Lin X, Tascilar M, Lee WH, et al: GSTP1 CpG island hypermethylation is responsible for the absence of GSTP1 expression in human prostate cancer cells. Am J Pathol. 159:1815–1826. 2001. View Article : Google Scholar
9.	Perry AS, Foley R, Woodson K and Lawler M: The emerging roles of DNA methylation in the clinical management of prostate cancer. Endocr Relat Cancer. 13:357–377. 2006. View Article : Google Scholar : PubMed/NCBI
10.	Hanson JA, Gillespie JW, Grover A, et al: Gene promoter methylation in prostate tumor-associated stromal cells. J Natl Cancer Inst. 98:255–261. 2006. View Article : Google Scholar : PubMed/NCBI
11.	Singal R, van Wert J and Bashambu M: Cytosine methylation represses glutathione S-transferase P1 (GSTP1) gene expression in human prostate cancer cells. Cancer Res. 61:4820–4826. 2001.PubMed/NCBI
12.	Okubo K and Matsubara K: Complementary DNA sequence (EST) collections and the expression information of the human genome. FEBS Lett. 403:225–229. 1997. View Article : Google Scholar : PubMed/NCBI
13.	Burke J, Wang H, Hide W and Davison DB: Alternative gene form discovery and candidate gene selection from gene indexing projects. Genome Res. 8:276–290. 1998. View Article : Google Scholar : PubMed/NCBI
14.	Liu XF, Olsson P, Wolfgang CD, Bera TK, Duray P, Lee B and Pastan I: PRAC: A novel small nuclear protein that is specifically expressed in human prostate and colon. Prostate. 47:125–131. 2001. View Article : Google Scholar
15.	Rozen S and Skaletsky H: Primer3 on the WWW for general users and for biologist programmers. Methods Mol Biol. 132:365–386. 2000.PubMed/NCBI
16.	Li LC and Dahiya R: MethPrimer: designing primers for methylation PCRs. Bioinformatics. 18:1427–1431. 2002. View Article : Google Scholar : PubMed/NCBI
17.	Andreoiu M and Cheng L: Multifocal prostate cancer: biologic, prognostic, and therapeutic implications. Hum Pathol. 41:781–793. 2010. View Article : Google Scholar : PubMed/NCBI
18.	Visakorpi T, Hyytinen E, Koivisto P, et al: In vivo amplification of the androgen receptor gene and progression of human prostate cancer. Nat Genet. 9:401–406. 1995. View Article : Google Scholar
19.	Montgomery BT, Young CY, Bilhartz DL, Andrews PE, Prescott JL, Thompson NF and Tindall DJ: Hormonal regulation of prostate-specific antigen (PSA) glycoprotein in the human prostatic adenocarcinoma cell line, LNCaP. Prostate. 21:63–73. 1992. View Article : Google Scholar : PubMed/NCBI
20.	Lee C, Sutkowski DM, Sensibar JA, et al: Regulation of proliferation and production of prostate-specific antigen in androgen-sensitive prostatic cancer cells, LNCaP, by dihydrotestosterone. Endocrinology. 136:796–803. 1995.PubMed/NCBI
21.	Olsson P, Motegi A, Bera TK, Lee B and Pastan I: PRAC2: a new gene expressed in human prostate and prostate cancer. Prostate. 56:123–130. 2003. View Article : Google Scholar
22.	Sreenath T, Orosz A, Fujita K and Bieberich CJ: Androgen-independent expression of hoxb-13 in the mouse prostate. Prostate. 41:203–207. 1999. View Article : Google Scholar
23.	Jones PA and Taylor SM: Cellular differentiation, cytidine analogs and DNA methylation. Cell. 20:85–93. 1980. View Article : Google Scholar : PubMed/NCBI
24.	Bender CM, Gonzalgo ML, Gonzales FA, Nguyen CT, Robertson KD and Jones PA: Roles of cell division and gene transcription in the methylation of CpG islands. Mol Cell Biol. 19:6690–6698. 1999.PubMed/NCBI
25.	Chiam K, Centenera MM, Butler LM, Tilley WD and Bianco-Miotto T: GSTP1 DNA methylation and expression status is indicative of 5-aza-2′-deoxycytidine efficacy in human prostate cancer cells. PLoS One. 6:e256342011. View Article : Google Scholar : PubMed/NCBI
26.	Cheng L, Bostwick DG, Li G, Wang Q, Hu N, Vortmeyer AO and Zhuang Z: Allelic imbalance in the clonal evolution of prostate carcinoma. Cancer. 85:2017–2022. 1999. View Article : Google Scholar : PubMed/NCBI
27.	Uchida T, Wang C, Sato T, et al: BRCA1 gene mutation and loss of heterozygosity on chromosome 17q21 in primary prostate cancer. Int J Cancer. 84:19–23. 1999. View Article : Google Scholar